A specific glucagon antiserum was generated in rabbits using a derivatisation of the methionine residue in glucagon. A sensitive and specific assay for glucagon has been developed. Interference with the assay system by plasma factors was abolished by both extraction of plasma samples and the production of glucagon-free plasma for each individual.
Problems connected with a radioimmunoassay for serum glucagon and for glucagon-like peptides were reviewed recently.' 2 Assays for pancreatic glucagon, which are specific as well as sensitive, are scarce.S 4- We report a novel radioimmunoassay for this hormone which is based on the derivatisation of the methionine residue described previously" and which fulfils the criteria of high sensitivity and specificity for 'true glucagon'.
Material and methods aqua dest), 10 fl.l lactoperoxidase (50 fl.g lactoperoxidase/ml acetate-acetic acid buffer), and 10 fl.l carrier-free iodine-125 solution (100 mCi/ml 0·001 N NaOH). After 10 minutes in the dark the reaction was terminated with 100 fl.1 sodium metabisulphate (2'5 mg Na 2S 2 0 5/5 ml, 0'05 M PBS, and 1O-4 M merthiolate).
Iodinated glucagon was first separated on a Sephadex G-15 column (10 x 180 mm). The final purification was carried out on a column (11 x 280 mm) of QAE-Sephadex A-25. 7 
SAMPLES
Blood from normal humans was collected in icechilled tubes containing aprotinin (500 KIU/ml) and EDTA (I mg/ml) and centrifuged after standing for 1 hour at 4°C. Plasma (0·5 mi) was extracted with ethanol (1' 8 ml96 %ethanol/ml plasma) immediately after centrifugation at 4°C. The supernatant was decanted and dried under nitrogen up to ± 0·5 ml and then extracted with diethylether before any further drying down. The dried product was stored at 4°C.
HORMONE-FREE PLASMA
After the dried product (from O' 5 ml human plasma) had been reconstituted in 300 fl.1 borate buffer (0'1 M, pH 8'6 including 0'25% bovine albumin, 10-4 M merthiolate, and 60 KIU aprotinin/ml), it LABELLED ANTIGEN was made hormone-free with solid-phase coupled Enzymatic iodination with lactoperoxidase was antibodies. carried out at room temperature (about 20°C) in Bio-Gel P 300 was activated with 25%glutaraldesmall glass vials. One hundred micrograms of porcine hyde; 10 ml of the activated beads was coupled to glucagon (Eli Lilly) was dissolved in 100 fl.l of 10 ml of a PBS solution containing 25 to 30 mg O'001 N NaOH. Five microlitres of this fresh solution isolated IgG (obtained after Na 2SO. precipitation was pipetted into the glass vial and mixed with 20 fl.l and dialysis of the goat antiserum.) 0·05 M sodium acetate-acetic acid buffer, pH 5'0, Remaining active groups were blocked with lysine 20 fl.l H 20 2 (4'5 fl.l H 20 2 of 30% by weight/l00 ml (0'1 M; pH 7'4). One hundred microlitres of 1:1, 118 ANTIBODIES Methylation of the methionine residue in glucagon was performed as described previously." Female New Zealand white rabbits were used for immunisation and each received an emulsion of 1 ml PBS containing 1 mg 27-S-methylglucagon and 1 ml complete Freund's adjuvant. They were injected intramuscularly at several sites. Every four weeks for six months they were challenged with O·5 mg 27-S-methylglucagon in 1 ml PBS and 1 ml incomplete Freund's adjuvant. A bulk antiserum was generated in goats by two-monthly immunisation with glucagon covalently coupled to albumin via the glutaraldehyde reaction," This antiserum reacted with both pancreatic glucagon and gut-GLI 1 (Novo Research). beads:borate buffer (pH 8'6) was dispensed into each plasma, reconstituted in 300 (Ll borate buffer (pH 8'6), mixed for 16 hours at 4°C, and separated by centrifugation (20 minutes, 2000 g). The supernatant (350 (Ll) was assayed by radioimmunoassay after centrifugation. 0·75 0·50 ,,' pg equivalents gut-GLI I tube Fig. 1 Glucagon standard curve obtained with antiglucagon antiserum K 1711 and apparent glucagon content ofgut-GLl1. GLUCAGON 
IODINATION
The elution pattern of radioactivity from anion exchange chromatography shows only one band (Fig. 2 ). This radioactivity peak corresponds to a specific activity of 490 (LCi/(Lg glucagon. A small proportion (5 %) of the applied radioactivity remained in the column as indicated by the black bar. The immunoreactivity was over 90 %. The relative amount of di-iodotyrosine was less than 0'2% of the total radioactivity as judged by thin-layer chromatography after treatment of the labelled material with O·5 mg pronase in 0·5 ml of 0·2 M Tris/HCl buffer (pH 8,0) for three days at 37°C.8 INTERFERENCE Sodium chloride interfered with the binding of antigen only at concentrations exceeding 500 mmol/l. Since an inhibition of the antigen-antibody reaction was observed by more than 50 % by heparin at a concentration of 25 U/ml, EDTA was used. No influence was found with EDTA.
No interference was found in the range examined of glucose (5-20 rnmol/l), urea (5-50 mmol/l), bovine albumin (0'2-2'0% w/v), and aprotinin (250-1000 KIV/ml).
Although aprotinin does not interfere, we prefer to make the conditions the same for standard curve and plasma, that is, 0·5 ml plasma (250 KIV aprotinin) and 0·35 ml standard solution (260 KIV aprotinin).
'"-pg 9 lue:agonI tube'
GEL FIL TRA TI ON
Blood samples were collected in tubes, as described before. Plasma (2'0 ml) was gel-filtered immediately on a Sephadex G-50 column (13 x 300 mm). Elution was carried out at 4°C with 0·1 M NH.HCO. (pH 8'0) containing 0'25% bovine albumin and 60 KIV aprotinin/ml, Each fraction was assayed against a standard buffer solution of pancreatic glucagon.
Results

ANTIBODY PROD UCTION
Out of 18 rabbits immunised with 27-S-methylglucagon two produced antibodies with high affinity. Figure 1 shows standard displacement curves of antiserum K 1711 with pancreatic glucagon and with gut-GLI 1. Cross-reaction of this antiserum with gut-GLI 1 is less than 1% up to 5 ng. The sensitivity for glucagon in buffer solution is better than 10 pg/tube. There was no cross-reaction with human gut extracts, with secretin, or with gastric inhibitory polypeptide at the highest amount tested (5 ng).
RADIOIMMUNOASSAY METHOD
Standard solutions of crystalline porcine glucagon (Eli Lilly) were freshly made each time in borate buffer (0'1 M; pH 8'6, containing 0'25% bovine albumin, 10-4 M merthiolate and aprotinin 750 KIV/ml).
Standard solution (350 (Ll) containing 0-500 pg glucagon, O: 5 ml patients' plasma (reconstituted in 350 (Ll borate buffer after extraction with ethanol and diethylether and drying under nitrogen), and o· 5 ml of each patient's hormone-free plasma (see above) were preincubated in duplicate with 50 (Ll diluted glucagon antiserum (K 1711, final dilution 1:10 0(0) for three days at 4°C. The fraction bound was measured two days after the addition of 100 (Ll radioactive glucagon (20 pg glucagon/reaction mixture).
The separation of free and antibody-bound glucagon was obtained with polyethylene glycol 6000 (final concentration 12· 5% vtv) after addition of 150 (Ll bovine serum to each assay tube.
The glucagon content in plasma was calculated by subtracting the immunoreactivity remaining after immunoadsorption from the apparent glucagon concentration in the same sample. Correction was made for the loss in adsorption (20-38 %). . . Lipids disturbed the RIA procedure by giving an unmanageable residue when the plasma was dried after ethanol extraction, especially when the plasma was assayed in a 1: I dilution. Extraction with diethylether, after ethanol extraction and evaporation of the ethanol under nitrogen, suppressed the interference with the binding of antigen by 40--70%.
Finally, there is interference of plasma proteins of high molecular weight (Fig. 3 ). There is a major IRG component of molecular weight >20000 with several smaller components including a 3500 molecular weight species similar to pancreatic glucagon. Amounts of the different fractions can vary considerably from plasma to plasma. After extraction of plasma with ethanol the IRG components of high molecular weight disappeared.
PROTEOLYTIC ENZYMES
When blood was collected from the same person, as described in Fig. 3 , without the addition of aprotinin, and the plasma was subjected to gel filtration, IRG components appeared after the 125I-glucagon marker and a peak-widening near the glucagon marker. This increased immunoreactivity might be the result of degradation of IRG components of high molecular weight and/or degradation of the 3500 molecular weight species. This degradation by proteolytic enzymes is not completely inhibited by the addition of aprotinin, shown by an assay after standing plasma for one week at 4°C, and varies considerably from plasma to plasma; neither is it completely inhibited when the plasma samples are frozen.
In order to eliminate this increase of immunologically active fragments from higher molecular weight components, aprotinin-enriched plasma was extracted with ethanol immediately after collection of blood and centrifugation at 4°C. After extraction of plasma with ethanol no increase of immunoreactivity in the low molecular weight zone was found with increasing time.
Pancreatic glucagon in human plasma remained fully immunoreactive for over one month when the plasma was stored at -20°C.
SOLID-PHASE COUPLED ANTIBODIES
A time course at 4°C of binding of 12SI-glucagon to the antibody Bio-Gel P 300 complex shows that after standing for 16 hours more than 95% of 125 1_ glucagon was bound. The variation in recovery in 10 normal human plasmas was small (5 %). Table 1 shows that the recovery of 125I-glucagon was independent of the plasma concentration of native glucagon over a broad range of concentrations.
The figures express the percentage of added radioactivity found in plasma, supernatant, and extract-(mean ± SD of four extractions) after an incubation period of 3 hours with an excess of the antibody Bio-Gel P 300 complex (100 fl.l). Control studies showed no leaching of the antibody from the complex into glucagon-free plasma.
In 20 normal human plasmas the results obtained with the charcoal method (1 ml plasma was made hormone-free with 50 mg charcoal suspended in O·5 ml aqua dest and continuously shaken for 1 hour at 4°C) were compared with the solid-phase coupled antibodies method. Higher glucagon concentrations were found for plasmas made glucagon-free with the charcoal method than with the solid-phase coupled antibodies method. The difference was sometimes as large as 100 pg glucagon/rnl. dilution curves were superimposable on the standard curve. The mean recoveries of exogenous glucagon added to plasma were 62 %, 70 %, 72 %, and 80 % for the addition of25, 100,250, and 500 pg glucagon/ml, respectively. Figure 4 shows the plasma glucagon levels in 90 fasting, normal subjects (aged 20--50 years). The distribution is slightly skewed to the right with a mean value of 50·3 ± 110 pg/ml (range 0--185 pg/rnl.
REFERENCE GROUPS
Fasting plasma glucagon levels
Glucagon tolerance test
Oral 50 g glucose tolerance tests were performed on 12 healthy volunteers after an overnight fast. Blood samples were taken immediately before and 1 hour after glucose administration and handled as described previously. Plasma glucagon concentration declined 30 Table 2 Within-and between-assayprecision ofglucagon measurements in normal human plasma PRECISION, SENSITIVITY, AND ACCURACY The within-and between-assay precision is shown in Table 2 . It is expressed by the coefficient of variation of the mean of triplicate determinations.
The assay sensitivity, taken as 2 SD from the % bound at zero hormone concentration, was 7· 5-10 pgjml,
The recovery of known amounts of glucagon added to plasma before extraction with ethanol and diethylether was determined by radioimmunoassay. Several dilutions of plasma with a high concentration of exogenous glucagon were assayed. Hormone-free plasma was used for dilution. The
Amount of glucagon
Within-assay added (pglm/) precision (%) 
Arginine tolerance test
Thirty grams of t-arginine monochloride dissolved in 300 ml water was infused over a period of 30 minutes in three fasting, healthy volunteers. The mean plasma glucagon concentration increased from a basal value of 30 ± 20 pg/ml to a peak of 135 ± 45 pgjml, After 1 hour values had declined to 50 ± 15 pg/ml.
Discussion
The measurement of pancreatic glucagon concentrations in plasma is complicated by the presence of different forms of glucagon immunoreactivity. Pancreatic glucagon, like most other small peptides, is by itself a poor immunogen. The problem of generating specific antisera against pancreatic glucagon may be overcome by the use of a glucagon derivative, for example, 27-S-methylglucagon. Another problem is the proteolytic activity in plasma. The addition of aprotinin, however, did not completely inhibit the degradation of glucagon and larger molecular weight components in plasma. To solve this problem extraction with ethanol immediately after blood collection and centrifugation was suggested. The same problem holds for standard glucagon solutions. It is recommended that fresh solutions should be made each time before use.
The instability of iodinated glucagon makes purification on a QAE-Sephadex A-25 column necessary every four weeks. There are several factors in plasma which may completely invalidate the radioimmunological determination of pancreatic glucagon. Some, but not all, of them are eliminated with an extraction of plasma with ethanol. The suggested extraction of plasma with diethylether also eliminated some of these factors. A control experiment of glucagon in buffer treated with peroxide-free diethylether, evaporated and analysed with an amino acid analyser, did not show any oxidation products of glucagon.
However, there still remained interfering factors in plasma. A direct comparison of pancreatic glucagon in plasma and pancreatic glucagon standard (either in buffer solution or in hormone-free pool plasma) was not possible. Our observations indicated that, instead of giving the same binding ratio, different glucagon-free plasmas affect antigen-antibody interaction to a considerably different degree. Each
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individual plasma should be measured against the same plasma, which first must be made hormone-free. The antibody Bio-Gel P 300 complex proved to be a much better immuno-absorbent compared with the antibody-Sepharose beads complex," This radioimmunoassay system fulfils the criteria of high sensitivity and specificity for pancreatic glucagon. In addition, the suppression of plasma glucagon concentrations after oral glucose administration and stimulation after arginine infusion to normal humans further attests to the specificity of the antiserum for pancreatic glucagon. Levels of pancreatic glucagon in this assay were lower than those reported from most other laboratories 10 11 but were similar to the values obtained by Alford et al. 9 A possible explanation for the lower levels is compensation for the variable inhibition produced by plasma.
